(Adds latest stories)
Oct 30 (Reuters) - Valeant Pharmaceuticals Inc is to sever all ties with pharmacy business Philidor Rx Services in the wake of criticism over the relationship between the two closely associated companies.
Valeant said Philidor had informed it that it would shut down operations as soon as possible.
Following are the key stories on the company, whose shares have lost half their market value since an August peak:
LATEST STORIES > Valeant cuts ties with beleaguered pharmacy Philidor > CVS, Express Scripts drop Valeant’s Philidor > Largest shareholder urges Valeant to pay down debt > FTC looking at Valeant’s contact lens dealings -source > ValueAct rallies Valeant investors -source > Controversial pharma CEO Shkreli bails on Valeant > From pilot to profit-maker, pharmacy rose quickly > Valeant raises detailed defense but doubts remain
EARLIER STORIES > Valeant vows to refute “phantom sales” allegations > Share price meltdown wipes $1.5 bln from CEO’s wealth > Slump poses big threat to small hedge funds > Looming M&A hiatus deals blow to investment banks > Plunge spotlights cracks in specialty pharma’s M&A facade > Shares plunge on short-seller scrutiny > Specialty pharmacies in spotlight > Class action lawsuit filed against Valeant > Valeant’s unusual CEO comes under fire > US CORP BOND WRAP-Healthcare rocked by more bad news > Falling secondary loan price pulls pharma down > Options volume explodes as traders dive for cover > Citron report on Valeant drags down biotechs > Meltdown costs investors billions; Ackman ups stake > CEO sees new drug pricing environment ahead > Clinton urges U.S. regulators to examine price hikes > Valeant subpoenaed by U.S. prosecutors
OPINION > Valeant’s clarification efforts further tangle web > Valeant sets tone for accounting scrutiny (Compiled by Nick Zieminski)